HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

gontivimab

trivalent Nanobody with antiviral properties against RSV

Also Known As:

ALX-0171

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Detalle, Laurent: 5 articles (01/2021 - 01/2016)
2.	Piedra, Pedro A: 2 articles (01/2021 - 01/2016)
3.	Millar, Andrena: 2 articles (01/2020 - 01/2016)
4.	Power, Ultan F: 2 articles (01/2020 - 01/2016)
5.	Allosery, Koen: 2 articles (01/2017 - 01/2016)
6.	Depla, Erik: 2 articles (11/2016 - 01/2016)
7.	Mas, Vicente: 2 articles (11/2016 - 01/2016)
8.	Melero, José A: 2 articles (11/2016 - 01/2016)
9.	Palomo, Concepción: 2 articles (11/2016 - 01/2016)
10.	Stortelers, Catelijne: 2 articles (11/2016 - 01/2016)

Related Diseases

1.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/2021 - "Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial." 01/01/2021 - "Previously healthy children aged between 28 days to younger than 24 months who were admitted to hospital with RSV acute severe lower respiratory tract infection were randomly assigned in three sequential safety cohorts (3:1) to receive nebulised ALX-0171 (cohort 1 received 3 mg/kg, cohort 2 received 6 mg/kg, and cohort 3 received 9 mg/kg) or placebo once daily for 3 days using web-based randomisation in the sequential safety part (first block size 12, subsequently four). " 01/01/2021 - "We aimed to assess the safety and antiviral activity of nebulised ALX-0171 in children admitted to hospital with RSV lower respiratory tract infection. "
2.	Respiratory Syncytial Virus Infections 01/01/2017 - "The latter is illustrated by the specific example of ALX-0171, a Nanobody in clinical development for the treatment of respiratory syncytial virus (RSV) infections." 01/01/2016 - "Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection." 01/01/2020 - "To characterize the therapeutic potential of ALX-0171, we exploited our well-differentiated primary pediatric bronchial epithelial cell (WD-PBEC)/RSV infection model, which replicates several hallmarks of RSV disease in vivo Using 2 clinical isolates (BT2a and Memphis 37), we compared the therapeutic potential of ALX-0171 with that of palivizumab, which is currently prescribed for RSV prophylaxis in high-risk infants. "
3.	Infections 01/01/2020 - "Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures." 11/01/2016 - "Notably, ALX-0171 showed a sizeable neutralization potency with most escape mutants, even with some of those selected with the Nanobody, and these findings make ALX-0171 an attractive antiviral for treatment of hRSV infections."

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Palivizumab